O^3'_,O5'-dimethyl-adenosine | 60037-50-5

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: O^3'_,O5'-dimethyl-adenosine
• 英文别名: (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-4-methoxy-5-(methoxymethyl)oxolan-3-ol
• CAS: 60037-50-5
• 化学式: C₁₂H₁₇N₅O₄
• 分子量: 295.298
• InChiKey: IHLCISFBURFUBT-WOUKDFQISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  118
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Adenosindeaminase inhibitor
  申请人：NIPPON ZOKI PHARMACEUTICAL CO., LTD.

  公开号：EP0601322A2

  公开（公告）日：1994-06-15

  The use of a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof wherein each of R₁, R₂ and R₃ which may be same or different is hydrogen or alkyl; and R and X have the meanings given in the specification, for the preparation of a medicament which is an adenosinedeaminase inhibitor is disclosed. Some of the compounds of formula (I) are novel compounds. They may be used for the making of a medicament which is for the prevention or therapy of ischemic heart diseases, diseases caused by cerebrovascular disorders, renal diseases and allergic diseases and of post-operative complicated diseases involved with activated oxygen which is generated in ischemic areas during the recirculation of blood after operations.

  使用以下通式（I）代表的化合物或其药学上可接受的盐 其中R₁、R₂和R₃可以相同或不同，各自为氢或烷基；R和X具有说明书中给出的含义。一些式（I）化合物是新型化合物。它们可用于制备预防或治疗缺血性心脏病、脑血管疾病、肾脏疾病和过敏性疾病以及术后复杂疾病的药物，这些疾病与术后血液再循环过程中在缺血区域产生的活性氧有关。
• Novel adenosine derivatives and pharmaceutical compositions containing them as an active ingredient
  申请人：NIPPON ZOKI PHARMACEUTICAL CO. LTD.

  公开号：EP0269574B1

  公开（公告）日：1992-03-18
• CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20170044206A1

  公开（公告）日：2017-02-16

  A class of polycyclic compounds of general formula (I), of general formula (I′), or of general formula (I″), wherein Base 1 , Base 2 , Y, Y a , X a , X a1 , X b , X b1 , X c , X c1 , X d , X d1 , R 1 , R 1a , R 2 , R 2a , R 3 , R 4 , R 4a , R 5 , R 6 , R 6a , R 7 , R 7a , R 8 , and R 8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
• STING AGONIST COMPRISING EXOSOMES COMBINED WITH IL-12 DISPLAYING EXOSOMES FOR TREATING A TUMOUR
  申请人：CODIAK BIOSCIENCES, INC.

  公开号：US20220395465A1

  公开（公告）日：2022-12-15

  Provided herein are methods of treating a tumor comprising administering (i) a composition comprising an extracellular vesicle and a STING agonist, e.g., exosome encapsulating STING agonists, in combination with (ii) an IL-12 moiety.
• US4843066A
  申请人：——

  公开号：US4843066A

  公开（公告）日：1989-06-27